Intuitive Surgical stock steadies after strong Q2 growth and Malaysia plant deal
Published on 08/26/2026 at 17:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical, Inc. (US46120E6023) stock is holding below recent peaks despite the company reporting double-digit revenue and earnings growth for the second quarter of 2026 and securing a new medical device manufacturing project in Malaysia as of August 26, 2026. A recent market overview shows the shares at $371.67 on August 25, 2026, giving the robotic surgery specialist a market capitalization of $131.97 billion and placing the price well under a consensus 12-month target of $508.68.
Q2 2026 delivers double-digit growth
Per a fresh coverage of Intuitive Surgical's latest results, the company generated revenue of $2.9 billion in the second quarter of 2026, representing growth of 18.4 percent versus the same quarter of 2025 when revenue was reported at roughly $2.45 billion. The same report states that adjusted earnings per share for Q2 2026 came in at $2.80, beating a cited consensus estimate of $2.48 and marking EPS growth of 27.9 percent year over year. That combination of mid- to high-teens top-line growth and near-30 percent earnings growth underlines that Intuitive Surgical is still expanding briskly despite a more mature installed base.
Operational momentum showed up clearly in system placements. Data compiled in the same coverage indicate that Intuitive Surgical placed 468 da Vinci robotic systems in the second quarter of 2026, up from 395 systems in the corresponding quarter of 2025. That increase of 73 systems translates to unit growth of roughly 18.5 percent year over year, broadly in line with the revenue expansion and suggesting that hardware sales and service streams are both contributing.
Procedure trends remain central to the story. A separate analysis of the earnings reaction notes that worldwide procedure growth using Intuitive Surgical platforms reached 16 percent in Q2 2026, while revenue growth clocked in at 19 percent. For investors, that gap means monetization per procedure is holding up or improving, even if volume growth moderates from earlier levels in the United States.
Guidance and valuation temper the share reaction
Despite the strong Q2 headline numbers, recent commentary on the stock emphasizes that the market's reaction has been muted, in part because of management's outlook for procedure growth. In the July earnings update covering results through the end of June 2026, Intuitive Surgical projected full-year da Vinci procedure growth in a range of 13.5 percent to 15.5 percent. That compares with the 16 percent growth actually delivered in the second quarter, implying that management expects growth to slow modestly over the remainder of the year.
For a company that has traded at a premium valuation for a prolonged period, a slight step-down in expected procedure growth can weigh on sentiment. One recent stock discussion points out that Intuitive Surgical stock has been having its weakest year since 2008, even though revenue in the most recent quarter still expanded by 19 percent. The tension between robust fundamental performance and a cautious market response is central to how investors are reassessing what they are willing to pay for the shares.
An analyst snapshot cited in the same-day broker overview puts the average 12-month price target for Intuitive Surgical at $508.68, with the shares at $371.67 on August 25, 2026. That gap of $137.01 implies potential upside of more than 36 percent if the consensus view proves accurate. At the same time, the report highlights a forward price-to-earnings multiple of 33.1, which, even after the stock's pullback, still reflects high expectations for sustained growth in procedures, system placements, and recurring service revenue.
Shares trade below highs ahead of next catalysts
Recent trading data show Intuitive Surgical stock at $371.67 on Nasdaq as of August 25, 2026, with the company valued at $131.97 billion. Over the past 52 weeks, the shares have spanned a range from $328.57 to $603.88, so the current price sits roughly $243 below the high and only modestly above the lower end of that band. That positioning indicates that the stock has already undergone a substantial de-rating from prior peaks, even while fundamentals stay solid.
On a European venue, a sector overview notes that the shares changed hands at 318.35 euros on Tradegate on August 25, 2026. That level corresponded to a decline of 0.66 percent over five days and a negative year-to-date performance of 4.95 percent. For investors who track global liquidity, the parallel moves in U.S. and German trading underline that the cautious view on valuation is not limited to one market.
Consensus views on the stock still lean constructive. A compiled broker summary shows a Moderate Buy recommendation from 31 analysts, with the average target at $508.68 and the shares trading far below that level. For long-term holders, the key question is whether Intuitive Surgical can sustain mid-teens procedure and revenue growth and continue to translate that into high-twenties earnings growth, thereby justifying the elevated multiple.
Malaysia plant expands manufacturing footprint
Beyond quarterly figures and valuation, Intuitive Surgical is also moving forward on its global manufacturing footprint. A new infrastructure announcement from Malaysia on August 26, 2026 detailed that a major construction subsidiary has been awarded a medical device manufacturing facility project valued at 454.5 million Malaysian ringgit for Intuitive Surgical Malaysia Sdn Bhd. The facility is planned for the Bandar Cassia Technology Park in Batu Kawan, Penang, an area that has attracted multiple semiconductor and high-tech manufacturing investments.
This Malaysian plant project, at roughly RM454.5 million, underscores Intuitive Surgical's commitment to expanding capacity closer to key growth markets in Asia. While the announcement does not yet quantify expected output in units or revenue, investors can infer that adding a dedicated medical device manufacturing facility is intended to support rising demand for robotic surgery systems and components in the region. In time, that could reduce logistics costs, shorten lead times, and strengthen the resilience of the supply chain for da Vinci systems and related instruments.
For a company whose growth hinges on both new system placements and instrument and accessory utilization, strategically located manufacturing can be an important enabler. If the Malaysian facility ultimately supports continued double-digit revenue growth without straining margins, it could become a meaningful long-term contributor even if it is not yet reflected directly in near-term earnings guidance.
Da Vinci system remains at the core
At the heart of Intuitive Surgical's business model is the da Vinci robotic surgery system, which integrates surgeon-controlled robotic arms, high-definition 3D visualization, and specialized instruments to enable minimally invasive procedures. In Q2 2026, the placement of 468 da Vinci systems, up from 395 a year earlier, reinforced that hospitals and surgical centers continue to adopt the platform at a healthy pace. Each new installation typically brings an associated stream of recurring revenue from instruments, accessories, and service contracts.
Worldwide procedure growth at 16 percent in the second quarter also shows that surgeons and patients are increasingly choosing da Vinci procedures across specialties, from urology and gynecology to general surgery. The company's full-year guidance for procedure growth of 13.5 percent to 15.5 percent suggests management expects continued expansion, albeit at a slightly slower pace than the latest quarterly figure. For investors, the balance between system growth, procedure volume, and monetization per procedure will remain the core driver of the long-term thesis.
Stock level and investor takeaways
As of the most recent Nasdaq trading snapshot on August 25, 2026, Intuitive Surgical stock was quoted at $371.67 in U.S. trading, with a 52-week high at $603.88 and a low at $328.57. That puts the shares more than 39 percent below the peak while still significantly above the trough, reflecting a market that has cooled on the valuation but not turned outright negative on the business. With a market cap of $131.97 billion at that price level, Intuitive Surgical remains one of the larger constituents of the health care equipment segment and a member of the Nasdaq-100 index.
For retail investors, the key numbers to monitor in coming quarters will be revenue growth relative to the 18.4 percent year-over-year pace seen in Q2 2026, EPS progression after the recent 27.9 percent jump, and procedure growth versus the 13.5 percent to 15.5 percent guided range. If the company maintains or exceeds these benchmarks while integrating new manufacturing capacity such as the Malaysian plant, the current gap between the share price and the consensus target could narrow. Conversely, any sustained slowdown in procedures or compression in margins would likely prompt a reassessment of the multiple the market is willing to assign.
Go deeper
Investor Relations
More on Intuitive Surgical stock
Da Vinci robotic surgery platform
Intuitive Surgical's flagship da Vinci robotic surgery platform is designed to help surgeons perform complex procedures through small incisions with enhanced precision and control. The system combines robotic arms that translate the surgeon's hand movements into scaled, tremor-filtered actions, a console that offers magnified 3D visualization, and a suite of interchangeable instruments tailored to specific surgical tasks. Over time, Intuitive Surgical has introduced successive generations of da Vinci systems with improved ergonomics, imaging, and software capabilities, supporting a broadening range of indications.
Intuitive Surgical stock and current level
Based on recent market data for Intuitive Surgical's Nasdaq listing, the shares were trading at $371.67 as of August 25, 2026 in U.S. hours, with a 52-week range of $328.57 to $603.88 and a market capitalization of $131.97 billion at that price. That level leaves the stock substantially below its 52-week high yet still well above the low, giving investors a clear numerical picture of how far sentiment has moderated from earlier optimism while recognizing that the company retains a sizable equity valuation in the health care equipment sector.
Fact box
Company: Intuitive Surgical, Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 25, 2026, 11:16 a.m. ET): $371.67 USD
Market cap: $131.97 billion (as of August 25, 2026)
Sector / Industry: Health Care / Health Care Equipment
Index membership: Nasdaq-100
